What’s ZIOPHARM Oncology, Inc. (ZIOP) Upside After Today’s Huge Increase?

December 7, 2017 - By Migdalia James

The stock of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) is a huge mover today! The stock increased 8.50% or $0.34 during the last trading session, reaching $4.34. About 2.10 million shares traded or 37.48% up from the average. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) has risen 1.75% since December 7, 2016 and is uptrending. It has underperformed by 14.95% the S&P500.
The move comes after 5 months positive chart setup for the $610.34M company. It was reported on Dec, 7 by Barchart.com. We have $4.51 PT which if reached, will make NASDAQ:ZIOP worth $24.41M more.

Analysts await ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) to report earnings on February, 15. They expect $-0.13 EPS, down 18.18 % or $0.02 from last year’s $-0.11 per share. After $-0.13 actual EPS reported by ZIOPHARM Oncology, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Ratings Coverage

Among 4 analysts covering Ziopharm Oncology (NASDAQ:ZIOP), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Ziopharm Oncology had 6 analyst reports since December 4, 2015 according to SRatingsIntel. Wells Fargo upgraded ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) on Wednesday, August 10 to “Market Perform” rating. Mizuho maintained ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) rating on Wednesday, May 11. Mizuho has “Neutral” rating and $7 target. The stock of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) has “Neutral” rating given on Monday, January 25 by Mizuho. On Friday, December 4 the stock rating was initiated by Wells Fargo with “Underperform”. The rating was initiated by Raymond James with “Market Perform” on Thursday, June 2.

More recent ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) news were published by: Globenewswire.com which released: “ZIOPHARM Oncology to Host Conference Call on November 20, 2017 at 10:15 am ET …” on November 17, 2017. Also Fool.com published the news titled: “The case for Celldex Therapeutics, Inc.” on November 30, 2017. Seekingalpha.com‘s news article titled: “ZIOPHARM tries to break downtrend, shares up 6%” with publication date: November 15, 2017 was also an interesting one.

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology. The company has market cap of $610.34 million. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to IntrexonÂ’s synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma . It currently has negative earnings. The Company’s synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.